Oklahoma Senate Bill SB1549

Oklahoma 2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/3/26

Caption

Civil liability; making vaccine manufacturer liable under certain conditions; directing certain relief. Effective date.

Summary

SB1549 creates a new civil liability cause of action against vaccine manufacturers when they advertise a vaccine in Oklahoma and the advertised vaccine causes harm or injury to an individual. The bill defines “advertise” broadly to include television, radio, print, internet, digital media, product placement, influencer promotions, and other paid promotional activity purchased by the manufacturer. It expressly excludes ordinary communications between health care providers and patients, as well as vaccine-related materials displayed in clinical settings. The bill also sets a limitations period, allowing an individual to file suit within three years after the cause of action accrues. If the claimant prevails, the court must award actual damages, court costs, and reasonable attorney fees. The measure would be codified in Title 76 of the Oklahoma Statutes and would take effect November 1, 2026.

Impact

SB1549 would add a new statutory basis for civil liability in Oklahoma targeted specifically at vaccine manufacturers engaged in advertising. It would expand potential exposure for manufacturers beyond traditional product liability theories by tying liability to promotional conduct and alleged resulting injury. The bill would also require courts to award damages, costs, and attorney fees to prevailing claimants, and it would establish a three-year filing deadline for these actions.

Sentiment

The available legislative record shows limited public debate, with no committee transcript or recorded votes included in the materials provided. Based on the bill’s referral to the Health and Human Services committee and its subject matter, the measure appears to be framed as a consumer-protection or accountability bill by its sponsor, but the text itself is highly adversarial toward vaccine manufacturers. Because there is no recorded discussion or vote history here, the overall sentiment cannot be measured beyond the bill’s clear policy direction.

Contention

The main point of contention is likely whether vaccine manufacturers should face special liability when they advertise vaccines, rather than being governed solely by existing product-liability and tort law. Supporters would likely argue the bill creates accountability for misleading or harmful promotion, while opponents would likely contend it singles out a lawful medical product category, could conflict with federal vaccine regulation or preemption principles, and may discourage vaccine promotion or availability. The bill’s broad definition of advertising and mandatory fee-shifting could also be contentious because they may increase litigation risk and costs for manufacturers.